NASDAQ: ACXP - Acurx Pharmaceuticals, Inc.

六个月盈利: -58.61%
股息率: 0.00%
部门: Healthcare

促销时间表 Acurx Pharmaceuticals, Inc.


关于公司 Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.

更多详情
It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.

IPO date 2021-06-25
ISIN US00510M1045
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.acurxpharma.com
Цена ао 2.08
每日价格变化: -0.6667% (0.9)
每周价格变化: +8.36% (0.825)
每月价格变化: -21.92% (1.145)
3个月内价格变化: -53.44% (1.92)
六个月内的价格变化: -58.61% (2.16)
每年价格变化: -76.66% (3.83)
3年内价格变化: -79.26% (4.31)
5年内价格变化: 0% (0.894)
10年价格变化: 0% (0.894)
年初以来价格变化: -52.45% (1.88)

低估

姓名 意义 年级
P/S 0 0
P/BV 10.05 1
P/E 0 0
EV/EBITDA -2.7 0
全部的: 2.63

效率

姓名 意义 年级
ROA, % -189.1 0
ROE, % -312.38 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA 0 10
全部的: 9.8

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 0 0
盈利能力 Ebitda, % 147.08 10
盈利能力 EPS, % 45.51 6
全部的: 7.2

ETF 分享, % 本年盈利能力, % 股息, %
iShares Micro-Cap ETF 0.00555 17.09 1.54048



导师 职称 支付 出生年份
Mr. Robert J. DeLuccia Co-Founder & Executive Chairman 701.54k 1946 (79 年)
Mr. Robert G. Shawah CPA, CPA Co-Founder & CFO 470.29k 1967 (58 年)
Mr. David P. Luci CPA, Esq., J.D. Co-Founder, President, CEO, Corporate Secretary & Director 1967 (58 年)

地址: United States, Staten Island. NY, 259 Liberty Avenue - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.acurxpharma.com